ReviewJournal of cardiovascular medicine (Hagerstown, Md.)2016
A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Review in Journal of cardiovascular medicine (Hagerstown, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Stable Cholesterol-Palmitic Acid Sterosomes as Smart Nanocarriers for pH-Sensitive Doxorubicin Delivery in Breast Cancer Therapy.Pharmaceutics · 2025Article
- Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies.Journal of ovarian research · 2025Review
- The role of stress echocardiography in identifying cardiotoxicity: an in-depth exploration.Frontiers in cardiovascular medicine · 2024Review
- Evaluation of acute toxicity and in vitro antitumor activity of a novel doxorubicin-loaded folate-coated pH-sensitive liposome.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.Current heart failure reports · 2023Review
- Assessment of Cardiovascular Function in Childhood Leukemia Survivors: The Role of the Right Heart.Children (Basel, Switzerland) · 2022Article
- Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury.Cells · 2021Article
- Anthracycline-induced cardiotoxicity: A case report and review of literature.World journal of cardiology · 2021Article
- Diversity of Cardiologic Issues in a Contemporary Cohort of Women With Breast Cancer.Frontiers in cardiovascular medicine · 2021Article
- Resveratrol in Cancer Patients: From Bench to Bedside.International journal of molecular sciences · 2020Review
- Vascular Damage - Coronary Artery Disease.Journal of cardiovascular echography · 2020Review
- Article
- Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.Heart failure reviews · 2019Review
- From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.Antioxidants & redox signaling · 2019Review
- Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Article
- An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline.Journal of translational medicine · 2018Article
- Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.British journal of pharmacology · 2017Article
- Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatinOncotarget · 2017Article
- Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.The international journal of cardiovascular imaging · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to the cardiologist who has not accumulated much experience in the field of cancer therapy, focuses on several topics, that is old and new mechanisms of cardiac toxicity, late cardiac toxicity, the importance of overall risk assessment, the key role of a cardiology consult before starting cancer therapy, and the pros and cons of primary and secondary prevention programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.